STOCK TITAN

Orchestra BioMed: RTW funds buy 1.2M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. (OBIO) common stock was purchased indirectly by certain affiliated funds managed by RTW Investments, LP: 1,200,000 shares at $5 per share on November 9, 2026. The reported indirect position afterward was 10,756,063 shares. RTW and Roderick Wong, M.D., RTW’s Managing Partner and Chief Investment Officer, were each listed as 10% owners and disclaimed beneficial ownership except to the extent of their respective pecuniary interests. The purchase was not reported as made under a Rule 10b5-1 plan.

Insider RTW INVESTMENTS, LP, WONG RODERICK
Role 10% Owner | 10% Owner
Bought 1,200,000 shs ($6.00M)
Increase in Position 12.6%
Type Security Shares Price Value
Purchase Common Stock F1 1,200,000 $5.00 $6.00M
Holdings After Transaction: Common Stock — 10,756,063 shares (Indirect, See footnote)
Holdings Before and After: Common Stock, 9,556,063 to 10,756,063 shares (Indirect, See footnote)
Other Insiders: 4 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (1)
  1. F1. Held by certain affiliated funds (the "RTW Funds") managed by RTW Investments, LP ("RTW"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their respective pecuniary interests therein.
Shares purchased 1,200,000 shares Indirect purchase on November 9, 2026
Purchase price $5 per share Indirect purchase on November 9, 2026
Reported post-transaction position 10,756,063 shares Indirect position following the November 9, 2026 purchase
beneficial ownership regulatory
"disclaim beneficial ownership of the reported securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interests regulatory
"except to the extent of their respective pecuniary interests therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OBIO shares were purchased and at what price?

Certain affiliated funds managed by RTW Investments, LP purchased 1,200,000 Orchestra BioMed common shares at $5 per share on November 9, 2026. The reported indirect position afterward was 10,756,063 shares.

Who reported the OBIO share purchase?

RTW Investments, LP and Roderick Wong, M.D., RTW’s Managing Partner and Chief Investment Officer, were listed as 10% owners. The shares were held by certain affiliated funds managed by RTW, and the reporting persons disclaimed beneficial ownership except to the extent of their respective pecuniary interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RTW INVESTMENTS, LP

(Last)(First)(Middle)
40 10TH AVENUE, FLOOR 7

(Street)
NEW YORK NEW YORK 10014

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/09/2026P1,200,000A$510,756,063ISee footnote(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
RTW INVESTMENTS, LP

(Last)(First)(Middle)
40 10TH AVENUE, FLOOR 7

(Street)
NEW YORK NEW YORK 10014

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
WONG RODERICK

(Last)(First)(Middle)
40 10TH AVENUE, FLOOR 7

(Street)
NEW YORK NEW YORK 10014

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. Held by certain affiliated funds (the "RTW Funds") managed by RTW Investments, LP ("RTW"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their respective pecuniary interests therein.
/s/ Roderick Wong, for RTW Investments, LP, By Roderick Wong, M.D., Managing Partner11/12/2026
/s/ Roderick Wong, By Roderick Wong, M.D.11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading